Neurodevelopmental Disorder CRISPR Knockout Cell Models for Drug Discovery

Neurodevelopmental disorders (NDDs) affect approximately 15% of children globally, according to the World Health Organization (WHO, 2023). These conditions, including autism spectrum disorder (ASD), intellectual disability (ID), and attention-deficit/hyperactivity disorder (ADHD), impose lifelong cognitive and behavioral challenges. The National Cancer Institute (NCI) does not track NDDs, but the CDC reports that 1 in 36 children in the U.S. is diagnosed with ASD (2023). Key risk factors include genetic mutations, prenatal exposure to toxins, and maternal infections. There is no cure; management relies on behavioral therapies and medications for co-occurring symptoms.

NDDs are ideal for mechanistic studies due to their strong genetic component, with hundreds of risk genes identified. Subtypes include syndromic (e.g., Rett syndrome, Fragile X) and non-syndromic forms. Public datasets like the Simons Foundation Autism Research Initiative (SFARI) Gene database and the Psychiatric Genomics Consortium (PGC) provide extensive genomic data. Open questions include the role of synaptic plasticity, neuronal network dysfunction, and gene-environment interactions. Gene-edited cell models enable precise dissection of these mechanisms.

NDDs involve disrupted neuronal development and function. Key pathways include:

• • Synaptic signaling: Imbalance in excitatory/inhibitory neurotransmission (e.g., NMDA receptor dysfunction).
• • Chromatin remodeling: Mutations in CHD8, MECP2, and other epigenetic regulators alter gene expression.
• • mTOR pathway: Hyperactivation in TSC1/TSC2 mutations leads to abnormal cell growth and synaptic pruning.
• • RNA metabolism: FMR1 silencing in Fragile X syndrome disrupts protein synthesis at synapses.

Data from ClinVar (NCBI, 2024) and SFARI Gene.

Key networks:

• • mTOR signaling: Hyperactive in TSC, leading to enlarged neurons and altered synaptic plasticity.
• • Wnt/beta-catenin: Mutations in CTNNB1 cause ID; disrupted neuronal migration.
• • MAPK/ERK: Altered in RASopathies (e.g., Noonan syndrome), affecting cell proliferation and differentiation.
• • GABAergic/glutamatergic balance: Imbalance due to mutations in GABRB3, GRIN2B, leading to hyperexcitability.

Organoids (cerebral organoids) recapitulate 3D brain development, enabling study of neuronal migration and network formation.

• • Mecp2 knockout mice: Model Rett syndrome; show motor and cognitive deficits.
• • Chd8 heterozygous mice: Model ASD; display social behavior abnormalities.
• • Tsc1/Tsc2 conditional knockout mice: Model tuberous sclerosis; develop seizures and learning deficits.
• • Fmr1 knockout mice: Model Fragile X; show altered synaptic plasticity.

CRISPR/Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications. For example:

• • MECP2 knockout in SH-SY5Y cells: Recapitulates Rett syndrome phenotypes.
• • CHD8 haploinsufficiency in iPSC-derived neurons: Models ASD-associated chromatin dysregulation.
• • TSC2 knockout in NPCs: Studies mTOR hyperactivation.

Commercially available, sequence-verified models accelerate research by providing consistent, validated tools. These models are available from commercial sources and can be customized for specific mutations.

CRISPR knockout/knock-in lines validate the role of candidate genes. For example:

• • MECP2 knockout in iPSC-derived neurons confirmed its role in synaptic maturation.
• • CHD8 knockout in neural progenitors showed altered gene expression profiles linked to ASD.

Isogenic pairs (e.g., TSC2+/+ vs TSC2-/-) enable screening for mTOR inhibitors. Resistance mechanisms can be studied by exposing edited cells to drugs and selecting for resistant clones.

CRISPR synthetic lethality screens identify genes that, when knocked out, are lethal only in the context of a specific NDD mutation. For example, screening in MECP2-deficient cells can reveal targets for therapeutic intervention.